Search results
Showing 481 to 495 of 2105 results for technology appraisal
Evidence-based recommendations on neratinib (Nerlynx) for extended adjuvant treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive early stage breast cancer in adults.
Evidence-based recommendations on bempedoic acid with ezetimibe (Nilemdo and Nustendi) for treating primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet in adults.
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating resectable locally advanced head and neck squamous cell carcinoma in adults.
Show all sections
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (TA440)
Evidence-based recommendations on pegylated liposomal irinotecan (Onivyde) for treating pancreatic cancer in adults.
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)
Evidence-based recommendations on ertugliflozin (Steglatro) as monotherapy or with metformin for treating type 2 diabetes in adults.
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA1120)
Evidence-based recommendations on avelumab (Bavencio) with axitinib for untreated advanced renal cell carcinoma in adults.
Evidence-based recommendations on tenecteplase (Metalyse) for treating acute ischaemic stroke in adults.
Evidence-based recommendations on somatrogon (Ngenla) for treating growth disturbance in children and young people aged 3 years and over.
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.
Evidence-based recommendations on erenumab (Aimovig) for preventing migraine in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Evidence-based recommendations on rituximab for treating relapsed or refractory chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on carfilzomib (Kyprolis) for previously treated multiple myeloma in adults.
Evidence-based recommendations on erlotinib (Tarceva) for treating EGFR-TK-positive non-small-cell lung cancer in adults.